Population-Based Assessment of Phenoconversion Potential in Switzerland: A Claims Data Study of Key Drug-Metabolizing Enzymes and Transporters
Open Access
- 1 May 2026
- journal article
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 19, 1-12
Abstract
Drug-drug-gene interactions can alter drug exposure and thereby increase the risk of clinically relevant outcomes, such as concentration-dependent toxicity (eg, tacrolimus toxicity in the context of altered CYP3A4/5 activity) or reduced treatment effectiveness. Despite their emerging relevance in clinical research, drug-drug-gene interactions remain understudied and are often ignored in clinical practice. Our objective was to assess the risk of phenoconversion by identifying potential drug-drug-gene interactions involving the transporters OATP1B1 and BCRP and the enzymes CYP2B6 and CYP3A4/5 in the Swiss population. Using claims data from the Helsana basic health insurance, we identified all persons of all ages with at least one drug claim between 2017 and 2021 and with Helsana basic health insurance coverage for at least one full year. For the five-year analysis, only persons with insurance for the entire five-year period were included. Within this study population, we assessed and ranked the frequency of potential drug-drug-gene interactions of a pharmacogenetic substrate and an inhibitor/inducer of OATP1B1, BCRP, CYP2B6, or CYP3A4/5. Potential drug-drug-gene interactions were defined as the co-occurrence of a pharmacogenetic substrate and an inhibitor/inducer within a 30- or 5-days window. During the entire five-year period, 18’523 (2.1%) and 12’645 (1.4%) individuals were exposed to potential drug-drug-gene interactions using the 30-day and 5-day windows, respectively. Potential drug-drug-gene interactions most frequently involved CYP3A4/5 (81.0% and 85.3%), followed by CYP2B6 (10.9% and 8.7%) and OATP1B1 (8.7% and 13.3%). The top three drug classes involved were nervous system drugs (75.1%), cardiovascular drugs (10.6%), and dermatologicals (4.0%). Quetiapine ranked first in the number of involved drug pairs, with quetiapine – metamizole being the predominant drug pair. In Switzerland, two out of 100 persons taking drugs metabolized or transported by OATP1B1, BCRP, CYP2B6, and CYP3A4/5 are at potential risk of phenoconversion, predominantly involving CYP3A4/5. These findings quantify real-world phenoconversion potential at the population level and underscore the need for outcome- and genotype-linked studies to determine clinical relevance. As this study was not designed to assess clinical outcomes, future genotype- and outcome-linked investigations are required to determine the actual impact on adverse drug reactions or treatment effectiveness.Keywords
This publication has 35 references indexed in Scilit:
- DrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Research, 2023
- Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressantsBiomedicine & Pharmacotherapy, 2022
- Drug–drug–gene interaction risk among opioid users in the U.S. Department of Veterans AffairsPain, 2022
- An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized MedicineClinical Pharmacology & Therapeutics, 2021
- Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequencesEuropean Geriatric Medicine, 2021
- An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genesJournal of Neural Transmission, 2018
- Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteersPharmacogenetics and Genomics, 2014
- Pharmacogenomics Knowledge for Personalized MedicineClinical Pharmacology & Therapeutics, 2012
- Pharmacogenetics and human genetic polymorphismsBiochemical Journal, 2010
- Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug MonitoringTherapeutic Drug Monitoring, 2007